It’s an interesting facet of the Top 10 highest-paid CEOs that only three of them are leading a Top 10 pharma company by revenue. On closer inspection this makes sense, as remuneration is more heavily linked to shareholder return and big pharma today aren’t in aggressive growth mode as compared to some of the names on this list.
The expectation on these CEOs that they will deliver above-average returns for their shareholders is high, and above-average returns cannot come from organic growth alone. Running through the list of companies and a key feature that most share is how active they are on the partnering, dealmaking and acquisition fronts. Case in point, just this week sees news of Pfizer’s acquisition of both Medivation and AstraZeneca’s small-molecule antibiotics business.
This excerpt is taken from EBD Group and Pharma Intelligence’s new report to be released at BioPharm America™ 2016 global life science partnering event, taking place in Boston, September 13–15. The full report, “Pursuing Excellence: Identifying the Industry’s Top Performers” will be introduced and distributed in the Dealmaking program track on Tuesday, September 13. For more information, see the program.
About the Author
Editor-in-Chief, InsightFollow on Twitter More Content by Erin Righetti